SCHEMBL206154

SCHEMBL206154

COCCCNC(=O)CCC(=O)NC1CCC(Cc2ccc(Cl)cc2)(N(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
ATM Q13315 1/20 0.40
CNR1 P21554 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084038 0.85 MAPT (0.40) TSHRLMNAKMT2AGAAATM
SCHEMBL208300 0.83 LMNA (0.50) TSHRHSD17B10LMNAKMT2ACNR1
SCHEMBL206987 0.83 POLB (0.56) TSHRLMNAKMT2AGAACYP1A2
SCHEMBL2989386 0.83 LMNA (0.45) LMNAGAACYP1A2CYP2C19HPGD
SCHEMBL2979269 0.82 LMNA (0.44) LMNAKMT2AGAACNR1HPGD
SCHEMBL206071 0.81 CNR1 (0.52) LMNAKMT2ACNR1CYP2C19HPGD
SCHEMBL206304 0.80 CNR1 (0.44) HTTLMNAKMT2ACNR1
SCHEMBL2986952 0.80 MEN1 (0.47) LMNAKMT2ACNR1MEN1
SCHEMBL2983415 0.79 MEN1 (0.45) KDM4EKMT2ACYP1A2CYP2C19HPGD
SCHEMBL206988 0.79 ALDH1A1 (0.51) TSHRHTTHSD17B10LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD TSHR 4464/4885HTT 422/4885HSD17B10 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.